Mesoblast Treats 300 Patients In Phase 3 Low Back Pain Trial For Rexlemestrocel-L

Mesoblast reported achieving the target enrollment of at least 300 patients in its pivotal Phase 3 MSD-DR004 trial of rexlemestrocel-L for chronic low back pain associated with inflammatory degeneration. The milestone is a positive clinical/operational step toward trial completion, but the article does not yet provide efficacy or safety results. Net impact is likely limited until readouts are released.

Analysis

Mesoblast reported achieving the target enrollment of at least 300 patients in its pivotal Phase 3 MSD-DR004 trial of rexlemestrocel-L for chronic low back pain associated with inflammatory degeneration. The milestone is a positive clinical/operational step toward trial completion, but the article does not yet provide efficacy or safety results. Net impact is likely limited until readouts are released.